Targeting EZH2 and EGFR therapeutic vulnerabilities of TNBC with a single chemical entity confers preclinical treatment advantage

Authors:
  • SSSaumya Ranjan Satrusal
    Saumya Ranjan Satrusal
  • ABArpita Banerjee
    Arpita Banerjee
  • ABArpon Biswas
    Arpon Biswas
  • GSGaurava Srivastava
    Gaurava Srivastava
  • ICIndranil Chatterjee
    Indranil Chatterjee
  • MKMuqtada Ali Khan
    Muqtada Ali Khan
  • BMBiswajit Mandal
    Biswajit Mandal
  • KTKiran Tripathi
    Kiran Tripathi
  • ASAbhipsa Sinha
    Abhipsa Sinha
  • AVAyushi Verma
    Ayushi Verma
  • PRPriyanka Rai
    Priyanka Rai
  • MAMahmood Akbar
    Mahmood Akbar

Abstract
No abstract available
Funding Information
  • Indian Council of Medical Research

This publication has 87 references indexed in Scilit: